Yervoy Toxicity Overview
Yervoy (ipilimumab), a CTLA-4 inhibitor for melanoma and other cancers, causes immune-related adverse events (irAEs) like colitis, hepatitis, dermatitis, and endocrinopathies. These occur in 60-80% of patients, with severe (grade 3-4) events in 20-40%, based on clinical trials and real-world data.[1][2]
Sex Differences in Clinical Trials
Pooled data from phase 3 trials (e.g., CA184-024, CheckMate studies) show no major differences in overall toxicity rates between males and females. Females report slightly higher rates of certain irAEs:
- Endocrine disorders (e.g., thyroiditis, hypophysitis): 15-20% in females vs. 10-15% in males.
- Dermatitis: Comparable (40-50% both sexes), but females experience more pruritus.
- Severe colitis or hepatitis: Similar incidence (10-15% grade 3-4 both sexes).[3][4]
Males have marginally higher rates of severe hepatic events in some analyses, but differences are not statistically significant across large datasets.
Real-World Evidence on Sex Disparities
Post-marketing studies and registries (e.g., VigiBase, FAERS) indicate females may discontinue Yervoy more often due to toxicity (odds ratio 1.2-1.5), linked to higher reporting of skin and endocrine issues. A 2022 meta-analysis of 5,000+ patients found:
- Females: 25% higher risk of grade 3+ endocrinopathies.
- Males: 10% higher risk of severe gastrointestinal events.
These gaps narrow with combination therapy (e.g., Yervoy + Opdivo).[5][6]
| Adverse Event | Female Rate (Grade 3-4) | Male Rate (Grade 3-4) | Key Notes |
|---------------|--------------------------|------------------------|-----------|
| Colitis | 12% | 14% | Male edge in severity[3] |
| Hepatitis | 8% | 10% | Dose-dependent[4] |
| Endocrinopathy | 18% | 12% | Female predominance[5] |
| Dermatitis | 5% | 4% | Similar[2] |
Why Differences Emerge
Hormonal factors (estrogen influencing immune response) and body composition (lower fat/muscle in females affecting dosing) contribute. Females often present with autoimmune-like symptoms more frequently. No adjustments to dosing by sex are recommended.[7]
Management and Patient Outcomes
Toxicity leads to discontinuation in 20-30% overall, similar by sex, but females average shorter treatment duration. Corticosteroids resolve most irAEs equally well. Long-term, sex does not impact survival differences from toxicity.[1][6]
Sources
[1]: FDA Yervoy Label
[2]: Hodi et al., NEJM 2010 (CA184-024 trial)
[3]: Wolchok et al., Clin Cancer Res 2017 (pooled analysis)
[4]: Larkin et al., NEJM 2015 (CheckMate 067)
[5]: Samaan et al., JAMA Oncol 2022 (meta-analysis)
[6]: DrugPatentWatch.com - Yervoy Safety Data
[7]: Balagula et al., J Clin Oncol 2011 (sex-based review)